Jeannie Chik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jeannie Chik has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
K. H. Wong
Queen Elizabeth Hospital
2 shared publicationsK. M. Cheung
Queen Elizabeth Hospital
2 shared publications- Bjørn Naume
Institute of Clinical Medicine University of Oslo Norway
1 shared publication C. W. Y. Kong
Queen Elizabeth Hospital
1 shared publication- C. W. Y. Kong
Queen Elizabeth Hospital
1 shared publication Carmen W. L. Leung
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China
1 shared publication
Latest Publications
- Open Access
- 20 December 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 204 (2) , 249-259
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Background: Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases. Methods: Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator’s choice (Study A) or exemestane + everolimus (Study B). Patients were randomized to receive radium-223 (55 kBq/kg) or placebo intravenously every 4 weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory). Results: In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal p values for radium-223 + ET versus placebo + ET were: SSE-FS 0.809 (0.610–1.072), p = 0.1389; rPFS 0.956 (0.759–1.205), p = 0.7039; OS 0.889 (0.660–1.199), p = 0.4410; and time to bone ALP progression 0.593 (0.379–0.926), p = 0.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3/4: 25.7% vs. 8.5%), with fractures/bone-associated events in 23.5% versus 23.9%. Conclusions: In patients with HR+ bone-metastatic breast cancer, numeric differences favoring radium-223 + ET over placebo + ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223 + ET versus placebo + ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs. Clinical trial registration numbers Study A: NCT02258464, registered October 7, 2014. Study B: NCT02258451, registered October 7, 2014.
- 20 December 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 204 (2) , 249-259
Open AccessRadium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Background: Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases. Methods: Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator’s choice (Study A) or exemestane + everolimus (Study B). Patients were randomized to receive radium-223 (55 kBq/kg) or placebo intravenously every 4 weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory). Results: In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal p values for radium-223 + ET versus placebo + ET were: SSE-FS 0.809 (0.610–1.072), p = 0.1389; rPFS 0.956 (0.759–1.205), p = 0.7039; OS 0.889 (0.660–1.199), p = 0.4410; and time to bone ALP progression 0.593 (0.379–0.926), p = 0.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3/4: 25.7% vs. 8.5%), with fractures/bone-associated events in 23.5% versus 23.9%. Conclusions: In patients with HR+ bone-metastatic breast cancer, numeric differences favoring radium-223 + ET over placebo + ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223 + ET versus placebo + ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs. Clinical trial registration numbers Study A: NCT02258464, registered October 7, 2014. Study B: NCT02258451, registered October 7, 2014.
- 29 September 2023
- Published by Springer Nature
- p. 249-255
External Radiotherapy for Orbital Apex Lesions: Principles and Practice
- 29 September 2023
- Published by Springer Nature
- p. 249-255
External Radiotherapy for Orbital Apex Lesions: Principles and Practice
- 29 September 2023
- Published by Springer Nature
- p. 273-281
External Photon Radiotherapy for Malignant Orbital Apex Lesions
- 29 September 2023
- Published by Springer Nature
- p. 273-281
External Photon Radiotherapy for Malignant Orbital Apex Lesions
- 29 September 2023
- Published by Springer Nature
- p. 257-271
External Photon Radiotherapy for Benign Orbital Apex Lesions
- 29 September 2023
- Published by Springer Nature
- p. 257-271
External Photon Radiotherapy for Benign Orbital Apex Lesions
- Open Access
- 1 November 2020
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 9 (6) , 4458-4466
Palliative radiation therapy for patients with orbital and ocular metastases
Palliative radiation therapy for patients with orbital and ocular metastases Jeannie Y. K. Chik, Carmen W. L. Leung, Kam Hung Wong
- 1 November 2020
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 9 (6) , 4458-4466
Open AccessPalliative radiation therapy for patients with orbital and ocular metastases
Palliative radiation therapy for patients with orbital and ocular metastases Jeannie Y. K. Chik, Carmen W. L. Leung, Kam Hung Wong